HUMASIS

HUMASIS CO. , LTD. , based in South Korea, specializes in innovative in vitro diagnostics and rapid diagnostic kits, enhancing accessibility and efficiency in healthcare. Founded in 2000 in Gunpo, South Korea, HUMASIS develops a range of diagnostic solutions.

Over the years, the company has focused on creating immunodiagnostic products and has expanded its operations to serve clients in 74 countries. The founder's previous entrepreneurial experiences have contributed to the company's strategic direction. HUMASIS has executed 1 deal to date, demonstrating its commitment to growth in the healthcare sector. Humasis specializes in developing a range of innovative in vitro diagnostic reagents and rapid diagnostic kits aimed at enhancing healthcare accessibility and efficiency.

The company's core product offerings include a variety of immunodiagnostic products designed for both quantitative and qualitative testing, which provide rapid results in critical situations such as emergency medical settings. Humasis also offers a remote health management platform that enables users to conduct easy and accurate self-testing, empowering individuals to take charge of their own health. The company serves a diverse client base across 74 countries, catering to healthcare providers, laboratories, and end-users who seek reliable and efficient diagnostic solutions. Their commitment to research and development has led to a robust portfolio of 163 products, significantly contributing to global health outcomes.

Humasis reported achieving a substantial export revenue of USD 30 mn in 2021, driven by its specialized offerings in the diagnostic sector. The company's revenue model includes B2B transactions where healthcare facilities, laboratories, and distributors purchase diagnostic kits and services directly from Humasis. These transactions involve partnerships with healthcare providers and wholesalers, ensuring that products are distributed widely in various markets. The flagship products, particularly in immunodiagnostics, serve as critical components in hospitals and clinics, where they are utilized for rapid patient assessments.

This structured transaction approach supports Humasis's ongoing growth and commitment to delivering high-quality health solutions internationally. HUMASIS plans to utilize its recent venture funding from Company K Partners to support the development of new diagnostic products and expand into additional markets. The company is currently designing new offerings aimed at enhancing user self-testing capabilities, with expected releases in the next 12 to 18 months. Geographically, HUMASIS targets expansion into Southeast Asian and European markets by the end of 2023, aiming to increase its footprint in these regions and improve healthcare accessibility through its innovative solutions.